PwC joins the Medicines Manufacturing Innovation Centre
In forming the partnership, PwC will join the founding partners of the Medicines Manufacturing Innovation Centre - CPI, the University of Strathclyde, GSK and AstraZeneca - to address challenges and maximise technology opportunities in the pharmaceutical supply chain.
The programme which is part-funded by Innovate UK and Scottish Enterprise, will strive to achieve this via its flagship project ‘Grand Challenge’. Which strive to advance emerging and disruptive technologies.
“We are excited to join the team at the Medicines Manufacturing Innovation Centre bringing PwC’s insights, experiences and connections. We are confident that this collaboration will have a big impact on the future of pharmaceutical manufacturing,” Johnathon Marshall, UK Pharma and Life Science Consulting lead at PwC.
What will PwC bring to the programme?
As part of the agreement, PwC plans to contribute significant value to the consortium by increasing business development opportunities, leveraging its global connectivity and brand authority.
In addition, PwC will act as a scout for new disruptive innovations, organisations and global opportunities, as well as develop market analysis and studies to communicate the value of current and future projects, and seek funding from private investors, industry and government.
“By partnering with PwC, the Medicines Manufacturing Innovation Centre will be able to work smarter, better and faster, ensuring more value to patients and the economy while advancing the UK’s already strong medicines manufacturing industry even further,” added Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre, Biologics & Quality at CPI.
“This partnership will support the Medicines Manufacturing Innovation Centre to reach new innovative organisations and markets, leading to more opportunities for industry to collaborate on next-generation technology,” concluded Neil Sheddan, Business Development Director at the Medicines Manufacturing Innovation Centre at CPI.
IHS Markit/CIPS: UK Manufacturing PMI near-record high
UK manufacturing trends
For the UK manufacturing sector, growth of output and new orders were both reported by IHS Markit and CIPS as among the best seen over the past seven years, which in turn has led to a strong increase in employment. Despite this, the sector continues to face supply chain delays and input shortages, which resulted in increased purchasing costs and record selling price inflation.
UK Manufacturing IHS Markit/CIPS Purchasing Managers’ Index® (PMI®)
Seasonally adjusted, IHS Markit/CIPS Purchasing Managers’ Index® (PMI®) rose to 60.9 in April, which was an increase compared to March (58.9) and above the estimated 60.7 for April.
Increasing for the eleventh consecutive month, the latest readings are the highest since July 1994 (61.0). The output growth for April has been attributed to the loosening of lockdown restrictions, improving demands and a rise in backlogged work.
“The manufacturing sector was flooded with optimism in April as the PMI rose to its highest level since July 1994, bolstered by strong levels of new orders and the end of lockdown restrictions opened the gates to business. It was primarily the home market that fuelled this upsurge in activity though more work from the US, Europe and China demonstrated there were also improvements in the global economy. This boom largely benefited corporates as output growth at small-scale producers continued to lag behind,” said Duncan Brock, Group Director at the Chartered Institute of Procurement & Supply.
In addition to expanding production, total new orders rose for its third consecutive month, which was attributed to a revival of domestic market conditions, stronger client confidence, parts of the economy reopening and improving global market conditions.
While new exports rose in April, the rate was reported as weaker in comparison to new orders. “Companies reported improved new work intakes from several trading partners, including mainland Europe, the US, China and South-East Asia. Large-sized manufacturers saw a substantial expansion in new export order intakes, compared to only a marginal rise at small-sized firms,” said IHS Markit/CIPS.
UK Manufacturing’s outlook
Remaining positive at the start of the second quarter, 66% of companies forecast that output will be higher in a year's time, which is attributed to expectations for less disruption related to COVID-19 and Brexit, economic recovery, improved client confidence and new product launches.
“Further loosening of COVID-19 restrictions at home and abroad led to another marked growth spurt at UK factories. The headline PMI rose to a near 27-year high, as output and new orders expanded at increased rates. The outlook for the sector is also increasingly positive, with two-thirds of manufacturers expecting output to be higher in one year’s time. Export growth remains relatively subdued, however, as small manufacturers struggle to export,” said Rob Dobson, Director at IHS Markit.
Adding to comments from IHS Markit and CIPS, , Managing Director of Freight and Logistics at Accenture Global said: “While today’s figures are positive overall, the worsening supply situation is still a concern, with rates of both input costs and selling price inflation running far above anything previously seen. Shipping delays and material shortages are driving huge backlogs of uncompleted work and the surge in manufacturing orders is leading to many firms struggling to boost operating capacity to keep up with demand. With business expectations becoming even more optimistic as the economy rebounds, the big question will be whether firms will be able to cope with the surging inflows of new orders.
“As ongoing supply chain issues are still at large, companies with wide international footprints should look to reassess their logistics strategies by running supply chain stress tests and simulations in order to respond quickly to upswings and variability in demand. A flexible and resilient supply chain will be a key way for businesses to remain both competitive and stable as we emerge from the pandemic”